首站-论文投稿智能助手
典型文献
ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome
文献摘要:
Dysregulation of NLRP3 inflammasome results in uncontrolled inflammation,which participates in various chronic diseases.TWIK2 potassium channel mediates potassium efflux that has been reported to be an essential upstream mechanism for ATP-induced NLRP3 inflammasome activation.Thus,TWIK2 potassium channel could be a potential drug target for NLRP3-related inflammatory diseases.In the present study we investigated the effects of known K2P channel modulators on TWIK2 channel expressed in a heterologous system.In order to increase plasma membrane expression and thus TWIK2 currents,a mutant channel with three mutations(TWIK21289A/L290A/Y308A)in the C-terminus was expressed in COS-7 cells.TWIK2 currents were assessed using whole-cell voltage-clamp recording.Among 6 known K2P channel modulators tested(DCPIB,quinine,fluoxetine,ML365,ML335,and TKDC),ML365 was the most potent TWIK2 channel blocker with an IC50 value of 4.07±1.5 μM.Furthermore,ML365 selectively inhibited TWIK2 without affecting TWIK1 or THIK1 channels.We showed that ML365(1,5 μM)concentration-dependently inhibited ATP-induced NLRP3 inflammasome activation in LPS-primed murine BMDMs,whereas it did not affect nigericin-induced NLRP3,or non-canonical,AIM2 and NLRC4 inflammasomes activation.Knockdown of TWIK2 significantly impaired the inhibitory effect of ML365 on ATP-induced NLRP3 inflammasome activation.Moreover,we demonstrated that pre-administration of ML365(1,10,25 mg/kg,ip)dose-dependently ameliorated LPS-induced endotoxic shock in mice.In a preliminary pharmacokinetic study conducted in rats,ML365 showed good absolute oral bioavailability with F value of 22.49%.In conclusion,ML365 provides a structural reference for future design of selective TWIK2 channel inhibitors in treating related inflammatory diseases.
文献关键词:
作者姓名:
Xiao-yan Wu;Jin-yan Lv;Shi-qing Zhang;Xin Yi;Zi-wei Xu;Yuan-xing Zhi;Bo-xin Zhao;Jian-xin Pang;Ken Kin Lam Yung;Shu-wen Liu;Ping-zheng Zhou
作者机构:
Guangdong Provincial Key Laboratory of New Drug Screening,School of Pharmaceutical Sciences,Southern Medical University,Guangzhou 510515,China;Department of Biology,Faculty of Science,Hong Kong Baptist University,Kowloon Tong,Hong Kong,China;Department of Pharmacy,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
引用格式:
[1]Xiao-yan Wu;Jin-yan Lv;Shi-qing Zhang;Xin Yi;Zi-wei Xu;Yuan-xing Zhi;Bo-xin Zhao;Jian-xin Pang;Ken Kin Lam Yung;Shu-wen Liu;Ping-zheng Zhou-.ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome)[J].中国药理学报(英文版),2022(04):992-1000
A类:
ML365,TWIK2,TWIK21289A,L290A,Y308A,DCPIB,ML335,TKDC,TWIK1,THIK1,endotoxic
B类:
inhibits,ATP,induced,NLRP3,Dysregulation,results,uncontrolled,inflammation,which,participates,various,chronic,diseases,potassium,mediates,efflux,that,has,been,reported,essential,upstream,mechanism,activation,Thus,could,potential,drug,target,related,inflammatory,In,present,study,investigated,effects,known,K2P,modulators,expressed,heterologous,system,order,increase,plasma,membrane,expression,thus,currents,mutant,three,mutations,terminus,was,COS,cells,were,assessed,using,whole,voltage,clamp,recording,Among,tested,quinine,fluoxetine,most,blocker,IC50,value,Furthermore,selectively,inhibited,without,affecting,channels,We,showed,concentration,dependently,LPS,primed,murine,BMDMs,whereas,did,not,nigericin,canonical,AIM2,NLRC4,inflammasomes,Knockdown,significantly,impaired,inhibitory,Moreover,demonstrated,administration,dose,ameliorated,shock,mice,preliminary,pharmacokinetic,conducted,rats,good,absolute,oral,bioavailability,conclusion,provides,structural,reference,future,design,inhibitors,treating
AB值:
0.471038
相似文献
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Novel soybean peptide iglycin ameliorates insulin resistance of high-fat diet fed C57BL/6J mice and differentiated 3T3L1 adipocytes with improvement of insulin signaling and mitochondrial function
Yinghuan Wu;Ran Zhao;Minxia Li;Huiyun Li;Zhengwang Chen;Yanying Zhao-Key Laboratory of Qinghai-Tibetan Plateau Animal Genetic Resource Reservation and Utilization of Ministry of Education,Key Laboratory of Qinghai-Tibetan Plateau Animal Genetic Resource Reservation and Utilization of Sichuan Province,College of Life Science and Technology,Southwest Minzu University,Chengdu 610041,China;Shandong Tianheng Inspection Co.,Ltd.,Heze 274000,China;Key Laboratory of Molecular Biophysics of Ministry of Education,School of Life Science and Technology,Huazhong University of Science and Technology,Wuhan 430074,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。